Stifel Financial
RYTM icon

Stifel Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Stifel Financial’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
12,689
+350
+3% +$31.6K ﹤0.01% 2339
2026
Q1 		$1.07M Sell
12,339
-908
-7% -$88.3K ﹤0.01% 2417
2025
Q4 		$1.42M Sell
13,247
-1,208
-8% -$128K ﹤0.01% 2201
2025
Q3 		$1.46M Sell
14,455
-3,722
-20% -$346K ﹤0.01% 2140
2025
Q2 		$1.15M Sell
18,177
-310
-2% -$19K ﹤0.01% 2234
2025
Q1 		$979K Sell
18,487
-1,029
-5% -$57.1K ﹤0.01% 2251
2024
Q4 		$1.09M Sell
19,516
-326
-2% -$18K ﹤0.01% 2193
2024
Q3 		$1.04M Sell
19,842
-8,216
-29% -$394K ﹤0.01% 2199
2024
Q2 		$1.15M Buy
28,058
+121
+0.4% +$4.83K ﹤0.01% 2080
2024
Q1 		$1.21M Sell
27,937
-2,688
-9% -$118K ﹤0.01% 2063
2023
Q4 		$1.41M Sell
30,625
-15,365
-33% -$485K ﹤0.01% 1917
2023
Q3 		$1.05M Sell
45,990
-706
-2% -$15.8K ﹤0.01% 2019
2023
Q2 		$770K Buy
46,696
+25,206
+117% +$455K ﹤0.01% 2245
2023
Q1 		$383K Buy
21,490
+2,110
+11% +$53K ﹤0.01% 2673
2022
Q4 		$564K Sell
19,380
-200
-1% -$5.14K ﹤0.01% 2402
2022
Q3 		$480K Buy
19,580
+619
+3% +$11.5K ﹤0.01% 2456
2022
Q2 		$79K Sell
18,961
-7,405
-28% -$40.5K ﹤0.01% 3186
2022
Q1 		$303K Sell
26,366
-47,547
-64% -$417K ﹤0.01% 2878
2021
Q4 		$738K Sell
73,913
-60,673
-45% -$682K ﹤0.01% 2343
2021
Q3 		$1.76M Sell
134,586
-46,828
-26% -$715K ﹤0.01% 1666
2021
Q2 		$3.55M Buy
181,414
+64,181
+55% +$1.33M 0.01% 1214
2021
Q1 		$2.49M Buy
117,233
+105,579
+906% +$3.06M ﹤0.01% 1378
2020
Q4 		$347K Buy
+11,654
New +$296K ﹤0.01% 2527
2018
Q3 		– Sell
-8,538
Closed -$266K – 2810
2018
Q2 		$266K Buy
+8,538
New +$233K ﹤0.01% 2373

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Stifel Financial's RYTM Position: Q2 2026 in Review

Stifel Financial increased its Rhythm Pharmaceuticals (RYTM) stake by 2.8% in Q2 2026, buying an estimated $31.6K and bringing the position to 12,689 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Stifel Financial first reported a position in RYTM in Q2 2018 and has held it in 24 quarters since. The position peaked at $3.55M in Q2 2021. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Stifel Financial held 12,689 shares of Rhythm Pharmaceuticals worth $1.41M as of Q2 2026.
  • Stifel Financial bought 350 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $31.6K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2339 holding.
  • Stifel Financial first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 24 quarters since.
  • Stifel Financial's Rhythm Pharmaceuticals position peaked at $3.55M in Q2 2021.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.